EC DECLARATION OF CONFORMITY

without the participation of a Notified body - diagnostic medical devices in vitro

Pursuant to Section 13(2) of Act No 22/1997 Coll., on the Technical Requirements for Products, and on a change and addition to certain laws, as amended, and pursuant to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices, the requirements of which have been adopted by Government Regulation 56/2015 Coll., on Technical Requirements for in vitro Diagnostic Medical Devices, as amended

MANUFACTURER

GeneProof a.s., Vídeňská 101/119, Dolní Heršpice, 619 00 Brno, Czech Republic www.geneproof.com

hereby declares that following product

GeneProof SARS-CoV-2 PCR Kit

Medical device type: Classification:

Intended purpose of the device:

in vitro diagnostic medical device other diagnostic medical devices

The kit is an in vitro nucleic acid amplification test intended for qualitative detection of SARS-CoV-2 genomic RNA by real-time polymerase chain reaction (PCR) method. The clinical specimens used for the detection are nasopharyngeal swab, anterior nasal swab and saliva in transport media. The diagnostic kit is intended for testing of individuals indicated for COVID-19 testing, i.e. symptomatic individuals with suspected COVID-19; asymptomatic individuals with known or suspected contact with COVID-19; asymptomatic individuals when the results will have an impact on the decision to use isolation/quarantine/personal protective equipment or individuals who need preventive testing. The Kit can be used in combination with a manual or automated extraction system or directly without RNA extraction. The kit is intended for diagnostics of SARS-CoV-2 and as an aid to diagnosis of COVID-19 and it is designed for professional use in laboratories with staff specifically trained in the techniques of real-time PCR. The target population is the EU population.

Variants:

COV2/GP/025, COV2/GP/100

complies with the basic requirements of Annex No. 1 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. and under normal use it is safe and effective for its intended purpose. The manufacturer has taken measures assuring compliance of all medical devices introduced into the market with their technical documentation and with the essential requirements.

Following currently valid version of the standards were applied to meet essential requirements:

ČSN EN ISO 13485 ed.2:2016

Medical device - QMS - Requirements for regulatory purposes

ČSN EN ISO 14971:2020

Medical device - QMS - Application of risk management to medical devices

ČSN EN ISO 18113-1:2012

In vitro diagnostic medical devices -- Information supplied by the manufacturer

(labelling) -- Part 1 Terms, definitions and general requirements

ČSN EN ISO 18113-2:2012

In vitro diagnostic medical devices -- Information supplied by the manufacturer

(labelling) -- Part 2 In vitro diagnostic reagents for professional use

ČSN EN ISO 15223-1:2017

Medical devices - Symbols to be used with medical device labels, labelling and

information to be supplied, Part1: General requirements

ČSN EN ISO 23640:2016

In vitro diagnostic medical devices - Evaluation of stability of in vitro diagnostic

reagents

Procedure described in Annex No. 3 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. were used to evaluate the basic characteristics of the product by the designated method.

Brno, May 18, 2022

Kamil ŠPLÍCHAL **Quality Assurance/Regulatory Affairs Chief Quality and Regulatory Affairs Officer** (Name, position and signature of authorized person) Manufacturer's stamp:

GeneProof

GeneProof a.s. / Vídeńská 119, CZ-619 00 Brno IČ/DIČ: CZ/26981947 / www.geneproof.com



